Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MGL-3196 in heterozygous familial hypercholesterolemia
NL-OMON45499Phase 2Active, not recruiting
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resmetirom in heterozygous familial hypercholesterolemia (HeFH) (3 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoint: Mean percent change from baseline in LDL-C. Started Apr 2017; status: active, not recruiting.
02
Drugs
resmetirom
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NL-OMON45499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45499.